203 results on '"Rubin, Brian P"'
Search Results
2. The practical utility of AI-assisted molecular profiling in the diagnosis and management of cancer of unknown primary: an updated review
3. Intra-host mutation rate of acute SARS-CoV-2 infection during the initial pandemic wave
4. Surgical Margins in Musculoskeletal Sarcoma
5. The oncogenic fusion protein TAZ::CAMTA1 promotes genomic instability and senescence through hypertranscription
6. Correction to: The practical utility of AI-assisted molecular profiling in the diagnosis and management of cancer of unknown primary: An updated review
7. Therapeutic targeting of TEAD transcription factors in cancer
8. Primary cutaneous extraskeletal osteosarcoma: a series of 16 cases
9. Machine learning for rhabdomyosarcoma histopathology
10. A clinicopathologic analysis of 54 cases of cutaneous myxoma
11. A Single-Arm Phase 2 Trial of Trametinib in Patients with Locally Advanced or Metastatic Epithelioid Hemangioendothelioma
12. Epithelioid hemangioendothelioma (EHE) with WWTR1::TFE3 gene fusion, a novel fusion variant
13. Correction to: Machine learning for rhabdomyosarcoma histopathology
14. Correction to: The practical utility of AI-assisted molecular profiling in the diagnosis and management of cancer of unknown primary: An updated review
15. CD117‐Targeted Intraoperative Imaging of Gastrointestinal Stromal Tumor Using a Stem‐Cell‐Factor‐Labeled Fluorophore
16. The practical utility of AI-assisted molecular profiling in the diagnosis and management of cancer of unknown primary: an updated review
17. Evading the Patronage Trap : Interest Representation in Mexico
18. Novel NCOA2/3‐rearranged low‐grade fibroblastic spindle cell tumors: A report of five cases
19. Supplementary Figure S2 from Loss of CDKN2A Cooperates with WWTR1(TAZ)–CAMTA1 Gene Fusion to Promote Tumor Progression in Epithelioid Hemangioendothelioma
20. Incidence, demographics, and survival of malignant hemangioendothelioma in the United States
21. Novel NCOA2/3‐rearranged low‐grade fibroblastic spindle cell tumors: A report of five cases.
22. Leveraging Hot Spots of TEAD–Coregulator Interactions in the Design of Direct Small Molecule Protein-Protein Interaction Disruptors Targeting Hippo Pathway Signaling
23. Data from NSD3–NUT Fusion Oncoprotein in NUT Midline Carcinoma: Implications for a Novel Oncogenic Mechanism
24. Supplementary Figure 4 from NSD3–NUT Fusion Oncoprotein in NUT Midline Carcinoma: Implications for a Novel Oncogenic Mechanism
25. Supplementary Methods, Figure Legends 1-4 from Evasion Mechanisms to Igf1r Inhibition in Rhabdomyosarcoma
26. Supplementary Figure 3 from NSD3–NUT Fusion Oncoprotein in NUT Midline Carcinoma: Implications for a Novel Oncogenic Mechanism
27. Supplementary Figures 1-9 from The Long Noncoding RNA NEAT1 Promotes Sarcoma Metastasis by Regulating RNA Splicing Pathways
28. Supplementary Figure 2 from NSD3–NUT Fusion Oncoprotein in NUT Midline Carcinoma: Implications for a Novel Oncogenic Mechanism
29. Supplementary Tables 1-6 from The Long Noncoding RNA NEAT1 Promotes Sarcoma Metastasis by Regulating RNA Splicing Pathways
30. Supplementary Figure 1 from NSD3–NUT Fusion Oncoprotein in NUT Midline Carcinoma: Implications for a Novel Oncogenic Mechanism
31. Data from The Long Noncoding RNA NEAT1 Promotes Sarcoma Metastasis by Regulating RNA Splicing Pathways
32. Data from Evasion Mechanisms to Igf1r Inhibition in Rhabdomyosarcoma
33. Supplementary Figures 1-4 from Evasion Mechanisms to Igf1r Inhibition in Rhabdomyosarcoma
34. Supplementary Table S1 from Loss of CDKN2A Cooperates with WWTR1(TAZ)–CAMTA1 Gene Fusion to Promote Tumor Progression in Epithelioid Hemangioendothelioma
35. Data from Immune Competency of a Hairless Mouse Strain for Improved Preclinical Studies in Genetically Engineered Mice
36. Supplementary Data from IL-4R Drives Dedifferentiation, Mitogenesis, and Metastasis in Rhabdomyosarcoma
37. Supplementary Figure 3 from Immune Competency of a Hairless Mouse Strain for Improved Preclinical Studies in Genetically Engineered Mice
38. Supplementary Tables 1-5, Supplementary Figures 1-6 from Olaratumab Exerts Antitumor Activity in Preclinical Models of Pediatric Bone and Soft Tissue Tumors through Inhibition of Platelet-Derived Growth Factor Receptor α
39. Supplementary Supplementary Methods, Supplementary Tables 1-6, Supplementary Figures 1-9 from Broad Spectrum Activity of the Checkpoint Kinase 1 Inhibitor Prexasertib as a Single Agent or Chemopotentiator Across a Range of Preclinical Pediatric Tumor Models
40. Supplementary Figure 1 from Immune Competency of a Hairless Mouse Strain for Improved Preclinical Studies in Genetically Engineered Mice
41. Supplementary Figure 2 from Immune Competency of a Hairless Mouse Strain for Improved Preclinical Studies in Genetically Engineered Mice
42. Supplementary Figure 4 from Credentialing a Preclinical Mouse Model of Alveolar Rhabdomyosarcoma
43. Supplementary Figure 3 from Proapoptotic Activity of Bortezomib in Gastrointestinal Stromal Tumor Cells
44. Supplementary Tables 1-7 from Credentialing a Preclinical Mouse Model of Alveolar Rhabdomyosarcoma
45. Supplementary Figure 1 from Credentialing a Preclinical Mouse Model of Alveolar Rhabdomyosarcoma
46. Data from Crosstalk between KIT and FGFR3 Promotes Gastrointestinal Stromal Tumor Cell Growth and Drug Resistance
47. Supplementary Figure 2 from Credentialing a Preclinical Mouse Model of Alveolar Rhabdomyosarcoma
48. Data from Credentialing a Preclinical Mouse Model of Alveolar Rhabdomyosarcoma
49. Supplementary Table 8 from Credentialing a Preclinical Mouse Model of Alveolar Rhabdomyosarcoma
50. Supplementary Figure Legends 1-5 from Credentialing a Preclinical Mouse Model of Alveolar Rhabdomyosarcoma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.